Skip to main content

Breast Cancer Recurrence: Role of Serum Tumor Markers CEA and CA 15-3

  • Chapter

Part of the Methods of Cancer Diagnosis, Therapy and Prognosis book series (HAYAT,volume 1)

Breast cancer is a heterogeneous, most frequent disease in women. All patients with breast cancer may develop progression or recurrence of the disease, and thus they need an effective lifelong follow-up (Lumachi et al., 2001). Breast cancer recurrence is a significant problem for clinicians. Even patients with early stage of the disease (stage I–II) have a recurrence rate of ∼ 30%, and local recurrences after conserving therapy have been reported from 6% to 12% at 5 and 10 years, respectively (Temple et al., 1999). In spite of advances in the diagnosis and therapy achieved over the past decade, a share of patients with breast cancer still develop relapse and metastases, from which they will ultimately die (Cheung et al., 2000).

Keywords

  • Breast Cancer
  • Advanced Breast Cancer
  • Breast Cancer Recurrence
  • Serum Tumor Marker
  • Cancer Antigen

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4020-8369-3_9
  • Chapter length: 7 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   309.00
Price excludes VAT (USA)
  • ISBN: 978-1-4020-8369-3
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   399.99
Price excludes VAT (USA)
Hardcover Book
USD   499.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Al-azawi, D., Kelly, G., Myers, E., McDermott, E.W., Hill, A.D.K., Duffy, M.J., and 'Higgins, N. 2006. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 6: 220–226

    PubMed  CrossRef  Google Scholar 

  • Bartsch, R., Wenzel, C., Pluschnig, U., Hussian, D., Sevelda, U., Altojai, G., Locker, G.J., Mader, R., Zielinski, C.C., and Steger, G.G. 2006. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment. BMC Cancer 6: 81–87

    PubMed  CrossRef  Google Scholar 

  • Cheung, K.L., Graves, C.R.L., and Robertson, J.F.R. 2000. Tumour marker measurement in the diagnosis and monitoring of breast cancer. Cancer Treat. Rev. 26: 91–102

    PubMed  CrossRef  CAS  Google Scholar 

  • Duffy, M.J. 2006. Serum tumor markers in breast cancer: are they of clinical value ? Clin. Chem. 52: 345–351

    PubMed  CrossRef  CAS  Google Scholar 

  • Given, M., Scott, M., Mc Grath, J.P., and Given, H. 2000. The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. Breast 9: 277–280

    PubMed  CrossRef  CAS  Google Scholar 

  • Haidopoulos, D., Konstadoulakis, M.M., Antonakis, P.T., Alexiou, D.G., Manouras, A.M., Katsaragakis, S.M., and Androulakis, G.F. 2000. Circulating anti-CEA antibodies in the sera of patients with breast cancer. Eur. J. Surg. Oncol. 26: 742–746

    PubMed  CrossRef  CAS  Google Scholar 

  • Keshaviah, A.S., Dellapasqua, S., Rotmensz, N., Lindtner, J., Crivellari, D., Collins, J., Colleoni, M . , Thurlimann, B., Mendiola, C., Aebi, S., Price, K.N., Pagani, O., Simoncini, E., Castiglione Gertsch, M., Gelber, R., Coates, A.S., and Goldhirsch, A. 2007. CA 15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann. Oncol. 18: 701–708

    PubMed  CrossRef  CAS  Google Scholar 

  • Khatcheressian, J.L., Wolff, A.C., Smith, T.J., Grunfeld, E., Muss, H.B., Vogel, V.G., Halberg, F., Somerfield, M.R., and Davidson, N.E. 2006. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J. Clin. Oncol. 24: 5091–5097

    PubMed  CrossRef  Google Scholar 

  • Li, J., Zhao, J., Yu, X., Lange, J., Kuerer, H., Krishnamurthy, S., Schilling, E., Khan, S.A., Sukumar, S., and Chan, D.W. 2005. Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. Clin. Cancer Res. 11: 8312–8320

    PubMed  CrossRef  CAS  Google Scholar 

  • Lumachi, F., and Basso, S.M.M. 2004. Serum tumor markers in patients with breast cancer. Expert Rev, Anticancer Ther. 4: 921–931

    CrossRef  CAS  Google Scholar 

  • Lumachi, F., Brandes, A.A., Ermani, M., Bruno, G., and Boccagni, P. 2000. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Anticancer Res. 20: 4751–4755

    PubMed  CAS  Google Scholar 

  • Lumachi, F., Ermani, M., Brandes, A.A., Basso, S.M., Basso, U., and Boccagni, P. 2001. Predictive value of different prognostic factors in breast cancer recurrences: multivariate analysis using a logistic regression model. Anticancer Res. 21: 4105–4108

    PubMed  CAS  Google Scholar 

  • Lumachi, F., Basso, S.M.M., Brandes, A.A., Pagano, D., and Ermani, M. 2004. Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer. Anticancer Res. 24: 3221–3224

    PubMed  CAS  Google Scholar 

  • McIntosh, M.W., Urban, N., and Karlan, B. 2002. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol. Biomarkers Prev. 11: 159–166

    PubMed  Google Scholar 

  • Molina, R., Barak, V. , van Dalen, A., Duffy, M.J., Einarsson, R., Gion, M., Hoike, H., Lamerz, R., Nap, M., Sölétormos, G., and Stieber, P. 2005. Tumor markers in breast cancer-European Group on tumor markers recommendation. Tumor Biol. 26: 281–293. Nicolini, A., Carpi, A., Ferrari, P., Anselmi, L., Spinelli, C., Conte, M., and Miccoli, P. 2000. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer 83: 1412–1417

    CrossRef  Google Scholar 

  • Nicolini, A., Carpi, A., Ferrari, P., Anselmi, L., Spinelli, C., Conte, M., and Miccoli, P. 2000. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br. J. Cancer 83: 1412–1417

    PubMed  CrossRef  CAS  Google Scholar 

  • Stearns, V. , Yamauchi, H., and Hayes, D.F. 1998. Circulating tumor markers in breast cancer:accepted utilities and novel prospects. Breast Cancer Res. Treat. 52: 239–259

    PubMed  CrossRef  CAS  Google Scholar 

  • Temple, L.K., Wang, E.E., and McLeod, R.S. 1999. Preventive health care, 1999 update: 3. Follow-up after breast cancer. Canadian Task Force on Preventive Health Care. CMAJ 161:1001–1008

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2008 Springer Science + Business Media B.V.

About this chapter

Cite this chapter

Lumachi, F., Basso, S.M.M., Basso, U. (2008). Breast Cancer Recurrence: Role of Serum Tumor Markers CEA and CA 15-3. In: Hayat, M.A. (eds) Methods of Cancer Diagnosis, Therapy and Prognosis. Methods of Cancer Diagnosis, Therapy and Prognosis, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-8369-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4020-8369-3_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-1-4020-8368-6

  • Online ISBN: 978-1-4020-8369-3

  • eBook Packages: MedicineMedicine (R0)